Cancer Res Treat.  2023 Jan;55(1):5-14. 10.4143/crt.2022.1460.

Top Ten Lessons Learned from Trials in Oligometastatic Cancers

• Tan VS
• Palma DA

• KMID: 2537987
• DOI: http://doi.org/10.4143/crt.2022.1460

Abstract

Recent evidence supports the role of aggressive local treatment in the oligometastatic setting. In this review, we discuss the top 10 lessons we have learned from trials in oligometastatic cancers. Major lessons learned pertain to definitions of oligometastatic disease, outcomes, toxicity, costs, and the combination of ablative therapies with systemic therapy, including immunotherapy. Barriers to accrual for trials and upcoming phase III trials are also reviewed. These lessons may help to inform clinical practice and may be the basis for future research in the oligometastatic space.

Keyword

Oligometastatic; Stereotactic; Metastases; Stereotactic ablative radiotherapy; Stereotactic body radiation therapy

Figure

• 

  Fig. 1 Summary of top ten lessons from trials in oligometastatic cancers infographic. RCT, randomized controlled trial; SABR, stereotactic ablative radiotherapy.

Reference

References

1. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011; 8:378–82.

2. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016; 17:1672–82.

3. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018; 4:e173501.

4. Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC. J Natl Cancer Inst. 2022; djac015.

5. Rim CH, Cho WK, Lee JH, Kim YS, Suh YG, Kim KH, et al. Role of local treatment for oligometastasis: a comparability-based meta-analysis. Cancer Res Treat. 2022; 54:953–69.

6. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148:157–66.

7. Ruers T, Punt C, Van Coevorden F, Pierie J, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012; 23:2619–26.

8. Palma DA, Olson R, Harrow S, Correa RJ, Schneiders F, Haasbeek CJ, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019; 19:816.

9. Bauman GS, Corkum MT, Fakir H, Nguyen TK, Palma DA. Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy. BMC Cancer. 2021; 21:405.

10. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21:e18–28.

11. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018; 36:446–53.

12. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020; 6:650–9.

13. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. LBA05: Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer (EXTEND): a multicenter, randomized phase II trial. In : 2022 American Society of Radiation Oncology Annual Meeting; 2022 Oct 23–26; San Antonio, TX, USA.

14. Treasure T, Farewell V, Macbeth F, Monson K, Williams NR, Brew-Graves C, et al. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial. Trials. 2019; 20:718.

15. Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, et al. NRG-BR002: a phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2022; 40(16 Suppl):1007.

16. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393:2051–8.

17. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy Vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019; 37:1558–65.

18. Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022; 40:3377–82.

19. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020; 38:2830–8.

20. Gulstene S, Lang P, Qu M, Laba JM, Yaremko BP, Rodrigues G, et al. Assessing treatment response after lung SABR: an evaluation of the predictive value of RECIST criteria. Int J Radiat Oncol Biol Phys. 2022; 114(3 Suppl):E373–4.

21. Jasper K, Stiles B, McDonald F, Palma DA. Practical management of oligometastatic non-small-cell lung cancer. J Clin Oncol. 2022; 40:635–41.

22. Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiat Oncol Biol Phys. 2022; 114:611–6.

23. Lehrer EJ, Singh R, Wang M, Chinchilli VM, Trifiletti DM, Ost P, et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol. 2021; 7:92–106.

24. Baker S, Jiang W, Mou B, Lund CR, Liu M, Bergman AM, et al. Progression-free survival and local control after SABR for up to 5 oligometastases: an analysis from the population-based phase 2 SABR-5 trial. Int J Radiat Oncol Biol Phys. 2022; 114:617–26.

25. Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, et al. Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. JAMA Oncol. 2022; 8:1644–50.

26. Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021; 22:98–106.

27. Olson R, Senan S, Harrow S, Gaede S, Louie A, Haasbeek C, et al. Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of the SABR-COMET randomized trial. Int J Radiat Oncol Biol Phys. 2019; 105:943–7.

28. Barry AS, Helou J, Bezjak A, Wong R, Dawson LA, Ringash J, et al. Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: a systematic review and individual patient data meta-analysis. Radiother Oncol. 2022; 173:163–9.

29. Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Look Hong NJ, et al. Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. CMAJ Open. 2020; 8:E191–8.

30. Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, et al. A systematic review of the cost-effectiveness of stereotactic radiation therapy for cancer oligometastases. Int J Radiat Oncol Biol Phys. 2022; 114:977–88.

31. Qu XM, Chen Y, Zaric GS, Senan S, Olson RA, Harrow S, et al. Is SABR cost-effective in oligometastatic cancer? An economic analysis of the SABR-COMET randomized trial. Int J Radiat Oncol Biol Phys. 2021; 109:1176–84.

32. Jin H, Chalkidou A, Hawkins M, Summers J, Eddy S, Peacock JL, et al. Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts: metastatic liver cancer and hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2021; 33:e143–54.

33. Siva S, Jones G, Bressel M, Shaw M, Chander S, Chu J, et al. Impact of medical operability and total metastatic ablation on outcomes after SABR for oligometastases. Int J Radiat Oncol Biol Phys. 2022; 114:862–70.

34. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986; 70:163–9.

35. Sha CM, Lehrer EJ, Hwang C, Trifiletti DM, Mackley HB, Drabick JJ, et al. Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis. Radiother Oncol. 2020; 151:141–8.

36. Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a Phase 2 trial. JAMA Oncol. 2019; 5:1283–90.

37. Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma: The RAPPORT trial. Eur Urol. 2022; 81:364–72.

38. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953; 26:234–41.

39. Marconi R, Strolin S, Bossi G, Strigari L. A meta-analysis of the abscopal effect in preclinical models: is the biologically effective dose a relevant physical trigger? PLoS One. 2017; 12:e0171559.

40. Hatten SJ Jr, Lehrer EJ, Liao J, Sha CM, Trifiletti DM, Siva S, et al. A patient-level data meta-analysis of the abscopal effect. Adv Radiat Oncol. 2022; 7:100909.

41. Theelen W, Chen D, Verma V, Hobbs BP, Peulen HM, Aerts J, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021; 9:467–75.

42. Spaas M, Sundahl N, Rottey S, Kruse V, de Maeseneer D, Duprez F, et al. OC-0625: Immuno-radiotherapy in solid tumors: preliminary results of the randomized phase 2 CHEERS trial. Radiother Oncol. 2021; 161:S490–1.

43. Masini C, Iotti C, De Giorgi U, Bellia RS, Buti S, Salaroli F, et al. Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma: results of the phase II NIVES study. Eur Urol. 2022; 81:274–82.

44. McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2021; 39:30–7.

45. Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022; 23:279–91.

46. De Jaeghere EA, Tuyaerts S, Van Nuffel AM, Belmans A, Bogaerts K, Baiden-Amissah R, et al. Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: results of the phase II PRIMMO study. Cancer Immunol Immunother. 2022. Aug. 12. [Epub]. https://doi.org/10.1007/s00262-022-03253-x .

47. Monjazeb AM, Giobbie-Hurder A, Lako A, Thrash EM, Brennick RC, Kao KZ, et al. A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer. Clin Cancer Res. 2021; 27:2470–80.

48. Bozorgmehr F, Hommertgen A, Krisam J, Lasitschka F, Kuon J, Maenz M, et al. Fostering efficacy of anti-PD-1-treatment: nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. BMC Cancer. 2019; 19:1074.

49. Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, et al. Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. BMC Cancer. 2019; 19:68.

50. Brockelmann PJ, Plutschow A, Greil R, Zijlstra JM, Illidge T, Fossa A, et al. Abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma (AERN): an international multicenter single-arm two-stage phase II GHSG trial. Blood. 2019; 134(Suppl 1):1547.

51. Stensland KD, McBride RB, Latif A, Wisnivesky J, Hendricks R, Roper N, et al. Adult cancer clinical trials that fail to complete: an epidemic? J Natl Cancer Inst. 2014; 106:dju229.

52. Nguyen TK, Nguyen EK, Warner A, Louie AV, Palma DA. Failed randomized clinical trials in radiation oncology: what can we learn? Int J Radiat Oncol Biol Phys. 2018; 101:1018–24.

53. Laba JM, Senan S, Schellenberg D, Harrow S, Mulroy L, Senthi S, et al. Identifying barriers to accrual in radiation oncology randomized trials. Curr Oncol. 2017; 24:e524–30.

54. Palma D. Stereotactic radiotherapy for oligo-progressive metastatic cancer (the STOP trial) [Internet]. Bethesda, MD: ClinicalTrials.gov;2016. [cited 2022 Oct 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02756793 .

55. Sherry AD, Bathala TK, Liu S, Fellman BM, Chun SG, Jasani N, et al. Definitive local consolidative therapy for oligometastatic solid tumors: results from the lead-in phase of the randomized basket trial EXTEND. Int J Radiat Oncol Biol Phys. 2022; 114:910–8.

56. European Organisation for Research and Treatment of Cancer - EORTC. Stereotactic body radiotherapy in patients with rare oligometaastatic cancers (OligoRARE) [Internet]. Bethesda, MD: ClinicalTrials.gov;2020. [cited 2022 Oct 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT04498767 .

57. Olson R, Mathews L, Liu M, Schellenberg D, Mou B, Berrang T, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer. 2020; 20:380.